DIVISLAB((Divi's Laboratories Limited))
09.11.2022 - Jefferies on Divislab Maintain Underperform CMP 3419 Target 3017
16.08.2022 - GS on Divislab Maintain Buy CMP 3744 Target 4550
16.08.2022 - HSBC on Divislab Maintain CMP 3744 Target 4325
24.05.2022 - MOTILALOSWAL on Divislab Maintain Buy CMP 3898 Target 4480
24.05.2022 - GS on Divislab Maintain Buy CMP 3898 Target 4850
24.05.2022 - BOFA on Divislab Maintain Neutral CMP 3898 Target 4300
24.05.2022 - Jefferies on Divislab Maintain Underperform CMP 3898 Target 3535
23.03.2022 - BOFA on Divislab Maintain Neutral CMP 4560 Target 4550
14.02.2022 - Jefferies on Divislab Maintain Hold CMP 4291 Target 4671
14.02.2022 - Kotak Instel Eq Divislab Maintain Reduce CMP 4291 Target 4125
14.02.2022 - GS on Divislab Maintain Buy CMP 4291 Target 5505
MACQUARIE ON DIVI'S LABS : 11.06.2021
* MAINTAIN OUTPERFORM TARGET: 4,806
* Macquarie maintains OUTPERFORM call on Divi's Labs, target at Rs 4,806/sh
* Commercialisation Of Molnupiravir API Could Present A Significant Opportunity
* It Is Barely Factored In Ours & Street Estimates
* Merck's US Deal Throws Light On Attractive Pricing & Potential Volumes
* Co Could Achieve $2.900 Cr Of Molnupiravir Sales in FY22
* Currently, Factoring In Barely 500 Cr Of Molnupiravir Sales In FY22